百奥赛图-B(02315)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02315 百奥赛图-B

休市中 12-12 16:08:07

28.300

+1.300

+4.81%

最高28.480	最低25.440	成交量79.60万
今开27.020	昨收27.000	日振幅11.26%
总市值126.50亿	流通市值31.41亿	总股本4.47亿
成交额2,187万	换手率0.72%	流通股本1.11亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02315","market":"HK","secType":"STK","nameCN":"百奥赛图-B","latestPrice":28.3,"timestamp":1765526887433,"preClose":27,"halted":0,"volume":796000,"delay":0,"floatShares":111000000,"shares":447000000,"eps":0.09296947777639444,"marketStatus":"休市中","change":1.3,"latestTime":"12-12 16:08:07","open":27.02,"high":28.48,"low":25.44,"amount":21865285,"amplitude":0.112593,"askPrice":28.34,"askSize":500,"bidPrice":28.16,"bidSize":9500,"shortable":0,"etf":0,"ttmEps":0.36738906751120526,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765762200000},"marketStatusCode":7,"adr":0,"listingDate":1661961600000,"exchange":"SEHK","adjPreClose":27,"openAndCloseTimeList":[[1765503000000,1765512000000],[1765515600000,1765526400000]],"volumeRatio":0.6006640506730659,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02315","defaultTab":"news","newsList":[{"id":"2590575299","title":"港股异动 | 百奥赛图-B(02315)盘中涨超5% 公司成功登陆科创板 构建A+H双平台上市格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2590575299","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590575299?lang=zh_cn&edition=full","pubTime":"2025-12-12 15:37","pubTimestamp":1765525071,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百奥赛图-B盘中涨超5%，截至发稿，涨4.15%，报28.12港元，成交额1950.98万港元。消息面上，12月10日，百奥赛图在上交所科创板挂牌上市。这是百奥赛图继2022年9月1日登陆香港交易所后，在深化资本市场布局、提升企业价值上又迈出的关键一步，标志着公司成功构建“H+A”双平台上市格局。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380843.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02315","BK1161","159982","688796"],"gpt_icon":0},{"id":"2590509062","title":"科创板挂牌后，百奥赛图“A+H” 双引擎欲推动中国创新药走向全球","url":"https://stock-news.laohu8.com/highlight/detail?id=2590509062","media":"野马财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590509062?lang=zh_cn&edition=full","pubTime":"2025-12-12 10:13","pubTimestamp":1765505596,"startTime":"0","endTime":"0","summary":"百奥赛图从上市到长期战略的逻辑延展。12月10日，公司在科创板成功上市，继2022年港交所挂牌后正式迈入“A+H”双地上市时代。这不仅是资本层面的突破，更象征着其“全人抗体库+靶点人源化小鼠库”双引擎体系从中国走向全球创新药产业的关键节点。2025年前三季度净利润达1.14亿元，经营净现金流进一步增长至2.63亿元。海外营收占比接近70%，表明百奥赛图的平台价值正加速被全球市场吸收，而不是局限在中国本土市场的波动之中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212101538a443a5b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212101538a443a5b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02315","06978","BK1161","BK1574"],"gpt_icon":0},{"id":"2590254249","title":"百奥赛图-B12月11日遭主力抛售92.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590254249","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590254249?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:15","pubTimestamp":1765440935,"startTime":"0","endTime":"0","summary":"12月11日, 百奥赛图-B股价跌7.53%，报收27.00元，成交金额2059.8万元，换手率0.67%，振幅12.05%，量比0.61。百奥赛图-B今日主力资金净流出92.8万元，连续4日净流出，上一交易日主力净流出531.1万元。该股近5个交易日下跌12.85%，主力资金累计净流出1211.2万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出2409.7万元，其中净流出天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211161823a6990ad9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211161823a6990ad9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02315","BK1161"],"gpt_icon":0},{"id":"2590584191","title":"百奥赛图-B(02315)12月10日发行4750万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2590584191","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590584191?lang=zh_cn&edition=full","pubTime":"2025-12-10 20:24","pubTimestamp":1765369446,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥赛图-B(02315)发布公告，于2025年12月10日发行4750万股A股;转换2.886亿股非上市股份为2.886亿股A股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380071.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02315","688796","399300","BK1161","159982"],"gpt_icon":0},{"id":"1180507970","title":"百奥赛图(688796)更新翌日披露报表，已发行A股增至3.36亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=1180507970","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180507970?lang=zh_cn&edition=full","pubTime":"2025-12-10 20:21","pubTimestamp":1765369276,"startTime":"0","endTime":"0","summary":"百奥赛图(北京)医药科技股份有限公司(股票代码：688796)于2025年12月10日发布翌日披露报表，公告显示公司已发行股份发生变动。\n公告称，公司通过A股发行及非上市股份转换，共新增47,500,000股A股，另有288,616,500股非上市股份转换为同等数量的A股，转换日期同为2025年12月10日。发行价格每股人民币26.68元。本次发行完成后，该公司A股数量增至336,116,500股，非上市股份则降至0股。\n公司同时确认，上述发行及转换均已履行相关上市规则及法律程序，并经公司董事会正式授权。公告由联席公司秘书王永亮签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02315"],"gpt_icon":0},{"id":"2590539201","title":"百奥赛图今日上市 发行价格26.68元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2590539201","media":"IT桔子","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590539201?lang=zh_cn&edition=full","pubTime":"2025-12-10 18:08","pubTimestamp":1765361290,"startTime":"0","endTime":"0","summary":"百奥赛图是一家以稳定、高效基因编辑技术平台为依托，以模式动物定制服务、重要模式动物开发与规模化繁殖与供应、体内药理药效评价服务、抗体药物研发外包服务为一体的高科技生物医药企业。拥有基因编辑平台、模式动物繁殖与供应平台、药理药效平台、抗体药物研发服务平台。百奥赛图今日在上海证券交易所科创板上市，公司证券代码为688796，发行价格26.68元/股，发行市盈率为519.12倍。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251210181157a72f885a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251210181157a72f885a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02315","BK1161"],"gpt_icon":0},{"id":"2590302362","title":"【券商聚焦】西部证券首予百奥赛图(02315)“买入”评级 后续分子进一步临床推进 平台价值有望进一步放大","url":"https://stock-news.laohu8.com/highlight/detail?id=2590302362","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590302362?lang=zh_cn&edition=full","pubTime":"2025-12-10 16:20","pubTimestamp":1765354802,"startTime":"0","endTime":"0","summary":"公司于2020年3月率先启动“千鼠万抗”计划，“抗体货架”模式，一方面节省了研发时间并降低了早期研发的不确定性，另一方面通过源头平行比较多个靶点，有望协助药企提高研发效率及临床转化的成功率。随着后续分子进一步临床推进，公司平台价值有望进一步放大。首次覆盖，给予“买入”评级。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971303","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02315","002673","688796"],"gpt_icon":0},{"id":"2590539734","title":"百奥赛图-B12月10日遭主力抛售531.1万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590539734","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590539734?lang=zh_cn&edition=full","pubTime":"2025-12-10 16:15","pubTimestamp":1765354506,"startTime":"0","endTime":"0","summary":"12月10日, 百奥赛图-B股价跌11.52%，报收29.20元，成交金额1.1亿元，换手率3.54%，振幅24.91%，量比7.17。百奥赛图-B今日主力资金净流出531.1万元，连续3日净流出，上一交易日主力净流出194.0万元。该股近5个交易日下跌4.81%，主力资金累计净流出1118.3万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出2013.3万元，其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251210161519953532f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251210161519953532f8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02315","BK1161"],"gpt_icon":0},{"id":"2590539202","title":"百奥赛图：抗体业务收入增长，获“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2590539202","media":"和讯网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590539202?lang=zh_cn&edition=full","pubTime":"2025-12-10 15:33","pubTimestamp":1765352025,"startTime":"0","endTime":"0","summary":"【12月10日，西部给予百奥赛图“买入”评级】百奥赛图是创新技术驱动新药研发的国际生物公司，旨在成全球新药发源地。其基于底层基因编辑技术，自研RenMice平台，可用于多种抗体发现。 公司临床前产品和服务增长快，全球化运营获海外MNC认证，实现规模化动物模型销售。“千鼠万抗”货架模式提升开发效率，抗体授权推动业绩弹性。 公司抗体业务始于2020年，当年收入0.41亿元，2025年上半年达1.63亿元。随着分子临床推进，平台价值有望放大。此次为首次覆盖，给予“买入”评级。本文由 AI 算法生成，仅作参考，不涉投资建议，使用风险自担","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251210172618a72f6feb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251210172618a72f6feb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02315","BK1161"],"gpt_icon":0},{"id":"2590130349","title":"百奥赛图-B(02315)大跌18.48% A股百奥赛图(688796)上海科创板首挂暂升136.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590130349","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590130349?lang=zh_cn&edition=full","pubTime":"2025-12-10 14:07","pubTimestamp":1765346826,"startTime":"0","endTime":"0","summary":"金吾财讯 | 百奥赛图-B(02315)股价大幅走低，创逾1个月低位，截至发稿，报26.9港元，跌18.48%，成交额6745.89万港元。A股百奥赛图(688796)今日上海科创板首日挂牌，暂升136.17%，报63.01元人民币，当前H股价格对A股折让61.49%。百奥赛图预计2025年营收为13.51亿元，同比增幅约为37.75%；预计扣非净利润约8027万元，较上年同期变动幅度约为249.50%。","market":"hk","thumbnail":"https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971287","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","399300","159982","688796","02315"],"gpt_icon":0},{"id":"2590397545","title":"市值280亿！“小白鼠”生意，撑起一个“A+H”股","url":"https://stock-news.laohu8.com/highlight/detail?id=2590397545","media":"直通IPO","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590397545?lang=zh_cn&edition=full","pubTime":"2025-12-10 11:39","pubTimestamp":1765337993,"startTime":"0","endTime":"0","summary":"简单来说，百奥赛图做的就是“小白鼠”的生意，即在药物研发的过程中，会先在动物身上进行实验，而这类动物也被称之为“模式动物”。近年来，百奥赛图凭借自主研发的Ren Mice全人抗体小鼠平台，以及“千鼠万抗”计划，在国内模式动物领域迅速崛起，与南模生物、药康生物并称为“三巨头”。期间，百奥赛图在2024年实现扭亏，主要源于公司研发费用大幅降低。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251210115942a43f1b7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251210115942a43f1b7b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02315","BK1161"],"gpt_icon":0},{"id":"2590539782","title":"百奥赛图科创板上市：预计年营收13.5亿 大涨120% 市值超260亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2590539782","media":"雷递网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590539782?lang=zh_cn&edition=full","pubTime":"2025-12-10 11:21","pubTimestamp":1765336918,"startTime":"0","endTime":"0","summary":"百奥赛图此次发行价为26.68元，发行4750万股，募资总额为12.67亿元。百奥赛图开盘价为58.7元，较发行价上涨120%；截至目前，公司市值约260亿元。百奥赛图预计2025年营收为13.51亿元，同比增幅约为37.75%；预计扣非净利润约8027万元，较上年同期变动幅度约为 249.50%，营业收入的快速增长使得公司净利润同样快速增长。截至本招股说明书签署日，沈月雷直接持有百奥赛图6.6086%股份，倪健直接持有百奥赛图7.2621%股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512101122579534bf85&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512101122579534bf85&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02315"],"gpt_icon":0},{"id":"2590373087","title":"百奥赛图-B已完成A股发行","url":"https://stock-news.laohu8.com/highlight/detail?id=2590373087","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590373087?lang=zh_cn&edition=full","pubTime":"2025-12-10 08:48","pubTimestamp":1765327680,"startTime":"0","endTime":"0","summary":"　　百奥赛图-B发布公告，本公司已完成A股发行。本公司A股将于2025年12月10日在上海证券交易所科创板上市并开始买卖。　　董事会同时宣布，根据公司法、公司章程等相关规定及本公司职工代表于2025年12月5日召开的职工代表大会结果，本公司职工代表大会推选李妍女士（李女士）担任第二届董事会职工代表董事。李女士的任期自本公司A股在科创板上市之日起生效，至第二届董事会任期届满之日止。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-12-10/doc-inhahnvh1919803.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159982","02315","399300","688796","BK1161"],"gpt_icon":0},{"id":"2590534112","title":"百奥赛图-B(02315.HK)：张海超辞任执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2590534112","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590534112?lang=zh_cn&edition=full","pubTime":"2025-12-09 21:37","pubTimestamp":1765287421,"startTime":"0","endTime":"0","summary":"格隆汇12月9日丨百奥赛图-B(02315.HK)宣布，张海超因公司内部工作调整辞任公司执行董事，于2025年12月10日生效。公司职工代表大会推选李妍担任第二届董事会职工代表董事。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251209/31854472.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688796","02315","BK1161"],"gpt_icon":0},{"id":"2590395194","title":"港股异动 | 百奥赛图-B(02315)涨超12%创新高 即将登陆A股科创板 公司千鼠万抗开始兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2590395194","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590395194?lang=zh_cn&edition=full","pubTime":"2025-12-09 10:43","pubTimestamp":1765248185,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百奥赛图-B(02315)涨超12%，高见35.86港元创新高。截至发稿，涨12.52%，报35.76港元，成交额1169.62万港元。消息面上，百奥赛图今早发布公告称，经上海证券交易所审核同意，百奥赛图(北京)医药科技股份有限公司发行的人民币普通股股票将于2025年12月10日在上海证券交易所科创板上市。华福证券此前研报指出，公司千鼠万抗开始兑现，抗体授权驱动业绩爆发。考虑公司业务的高成长性及高壁垒，临床前动物及药理药效评价基本盘稳固，抗体开发业务已逐步进入业绩兑现期，叠加潜在的新药管线具有潜力，首予“买入”评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379162.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02315","399300","BK1161","688796","159982"],"gpt_icon":0},{"id":"2590673263","title":"百奥赛图-B将于12月10日在上海证券交易所科创板上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2590673263","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590673263?lang=zh_cn&edition=full","pubTime":"2025-12-09 08:37","pubTimestamp":1765240620,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　百奥赛图-B（02315）发布公告，经上海证券交易所审核同意，百奥赛图（北京）医药科技股份有限公司发行的人民币普通股股票将于2025年12月10日在上海证券交易所科创板上市。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-12-09/doc-inhaecqr1087605.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159982","02315","688796","BK1161"],"gpt_icon":0},{"id":"2590505350","title":"Cosmo脱发新药三期临床告捷；石药集团双靶点新药FDA临床批准；百奥赛图B7H3/PTK7双抗ADC获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2590505350","media":"药财社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590505350?lang=zh_cn&edition=full","pubTime":"2025-12-08 19:02","pubTimestamp":1765191720,"startTime":"0","endTime":"0","summary":"2石药集团双靶点新药FDA临床批准12月5日，石药集团宣布，本集团开发的GLP-1/GIP受体双偏向性激动多肽注射液已获得美国食品药品监督管理局批准，可在美国开展临床试验。3百奥赛图B7H3/PTK7双抗ADC获FDA批准2025年12月5日，百奥赛图宣布，其合作伙伴IDEAYA 公司已获得美国FDA的临床试验用新药批准，推进同类首创B7H3/PTK7双特异性抗体偶联物项目的I期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208200527a72b1d02&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208200527a72b1d02&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0880133367.SGD","IE00B031HY20.USD","LU1226287875.USD","LU1328277881.USD","IE0008369823.USD","LU0501845795.SGD","LU1008478684.HKD","LU1226288170.HKD","LU1226288253.USD","BK1515","LU0315179316.USD","IE0008368742.USD","LU1226287792.SGD","LU0140636845.USD","LU1813983027.USD","IE00BZ08YT58.USD","LU1951186391.HKD","LU1960683339.HKD","HK0000165453.HKD","IE00BZ08YR35.GBP","LU1807302812.USD","LU1226287529.USD","BK1191","02315","BK1521","IE00B543WZ88.USD","LU1993786604.SGD","LU1152091754.HKD","LU0072913022.USD","LU0314109678.HKD","IE00BZ08YS42.EUR","01093","SG9999004220.SGD","LU1152091168.USD","IE00B5MMRT66.SGD","LU0326950275.SGD","LU2039709279.SGD","LU0067412154.USD","BK1161"],"gpt_icon":1},{"id":"2589448869","title":"港股异动 | 百奥赛图-B(02315)涨超3% 授权IDEAYA双抗ADC项目IDE034获FDA IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2589448869","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589448869?lang=zh_cn&edition=full","pubTime":"2025-12-05 14:46","pubTimestamp":1764917191,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百奥赛图-B涨超3%，截至发稿，涨2.84%，报31.86港元，成交1299.1万港元。IDEAYA预计将在2026年第一季度开始患者入组，初步评估B7H3和PTK7共表达的实体瘤类型，包括肺癌、结直肠癌、头颈癌及卵巢/妇科肿瘤。此外，IDEAYA计划探索IDE034与其PARG抑制剂IDE161的联合治疗策略，以增强疗效持续性，并计划在2026年上半年重要医学会议上分享更多支持PARG与TOP1 ADC联合治疗机制的数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4080","BK1161","02315","688796","IND","BK4231","ADC"],"gpt_icon":0},{"id":"2589855702","title":"百奥赛图-B(02315)业务合作伙伴IDEAYA取得美国食品药品监督管理局对IDE034的IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2589855702","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589855702?lang=zh_cn&edition=full","pubTime":"2025-12-05 08:09","pubTimestamp":1764893379,"startTime":"0","endTime":"0","summary":"IDEAYA预计将在2026年第一季度开始患者入组，初步评估B7H3和PTK7共表达的实体瘤类型，包括肺癌、结直肠癌、头颈癌及卵巢╱ 妇科肿瘤。B7H3和PTK7在肺癌、结直肠癌及头颈癌等实体瘤中的共表达比例分别约为30%、46% 和27%，显示IDE034广泛的临床适应症潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377962.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688796","IND","02315","BK1161"],"gpt_icon":1},{"id":"2589383664","title":"百奥赛图连续三年荣获“最具价值医药及医疗公司”奖项，彰显卓越创新实力与行业影响力","url":"https://stock-news.laohu8.com/highlight/detail?id=2589383664","media":"百奥赛图","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589383664?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:00","pubTimestamp":1764846017,"startTime":"0","endTime":"0","summary":"2025年12月3日，在由智通财经与新智基金网联合主办、冬日暖阳 Donova 独家承办的 “第十届智通财经上市公司颁奖盛典” 上，百奥赛图再次荣获“最具价值医药及医疗公司”奖项。百奥赛图采用开放灵活的模式持续推进全球商务合作，截至2025年上半年，公司累计签署约300项抗体合作协议，成为全球抗体药物研发的重要赋能者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204200217a4cc9c7e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204200217a4cc9c7e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1515","BK1574","02315","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bbctg.com.cn","stockEarnings":[{"period":"1week","weight":-0.1211},{"period":"1month","weight":-0.0691},{"period":"3month","weight":0.2304},{"period":"6month","weight":0.2719},{"period":"1year","weight":2.8243},{"period":"ytd","weight":2.3294}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":-0.0351},{"period":"3month","weight":-0.0156},{"period":"6month","weight":0.0872},{"period":"1year","weight":0.2736},{"period":"ytd","weight":0.295}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"百奥赛图（北京）医药科技股份有限公司是一家主要提供抗体药物研发和临床前研究服务的中国公司。该公司运营五个分部。基因编辑服务分部提供基于动物和细胞的定制化基因编辑服务。临床前药理药效评估分部提供用于药物疗效和毒性评估的临床前药理学服务。模式动物销售分部培育和销售外用和内用模式动物，亦向客户授出若干模式动物的许可。抗体开发分部识别有潜力成为候选药物的抗体，并就潜在治疗性抗体分子对外授权或与合作伙伴合作。创新药开发分部研发创新药，专注肿瘤学和自身免疫性疾病治疗。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.105956},{"month":2,"riseRate":0.666667,"avgChangeRate":0.052338},{"month":3,"riseRate":0.333333,"avgChangeRate":0.185414},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.066586},{"month":5,"riseRate":0.666667,"avgChangeRate":0.14952},{"month":6,"riseRate":0.333333,"avgChangeRate":0.011218},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.033427},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.055975},{"month":9,"riseRate":0.666667,"avgChangeRate":0.092895},{"month":10,"riseRate":0.25,"avgChangeRate":-0.096483},{"month":11,"riseRate":0.5,"avgChangeRate":0.009059},{"month":12,"riseRate":0.25,"avgChangeRate":0.082632}],"exchange":"SEHK","name":"百奥赛图-B","nameEN":"BIOCYTOGEN-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百奥赛图-B(02315)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百奥赛图-B(02315)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百奥赛图-B,02315,百奥赛图-B股票,百奥赛图-B股票老虎,百奥赛图-B股票老虎国际,百奥赛图-B行情,百奥赛图-B股票行情,百奥赛图-B股价,百奥赛图-B股市,百奥赛图-B股票价格,百奥赛图-B股票交易,百奥赛图-B股票购买,百奥赛图-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百奥赛图-B(02315)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百奥赛图-B(02315)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}